Sun Pharma is set to nearly double its revenue to $12 billion with the acquisition of Organon, creating a global pharmaceutical giant. The deal leverages Organon’s strengths in women’s health, biosimilars, and established brands, aiming for significant growth despite geopolitical concerns. Integration plans and manageable debt are key to the strategic move.
Sebi approves 3 IPOs of Cosmic PV, Monomark, RKB Global along with NSE
SEBI has approved IPOs for Cosmic PV Power, Monomark Engineering, and RKB Global, alongside the National Stock Exchange’s major public offer. These approvals highlight a
September 4, 2026